Her-2/neu amplification determined by real-time quantitative PCR and its association with clinical outcome of breast cancer in Thailand.
作者： Songkhun Vinyuvat , Wichai Purisa , Sunanta Chariyalertsak
DOI:
关键词:
摘要: HER-2/neu has been found to be amplified or overexpressed in about 20-30% of breast cancers, association with negative prognosticators and shortened survival. Determination status breast-cancer patients, select for adjuvant treatment trastuzumab, is becoming standard clinical practice. This study aimed investigate by real-time quantitative polymerase chain reaction (PCR), allowing accurate precise quantification amplification tumor tissues. We evaluated 112 samples, which 42 (37.5%) had amplification. After a mean follow-up period 71 months, was significantly associated increased risk death (HR = 6.367, 95% CI 1.787-22.684), even after adjusting age, stage, size, lymph-node status, histologic grade. These findings support prognostic role suggest that PCR analysis represents an alternative technique establishing routine
koreascience.or.kr 参考文章(32)
B. Tetu, V. Plante, J. Brisson, P. Bernard, p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Modern Pathology. ,vol. 11, pp. 823- 830 ,(1998)
Lise Mette Gjerdrum, Boe Sandahl Sorensen, Eigil Kjeldsen, Flemming Brandt Sorensen, Ebba Nexo, Stephen Hamilton-Dutoit, Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma The Journal of Molecular Diagnostics. ,vol. 6, pp. 42- 51 ,(2004) , 10.1016/S1525-1578(10)60490-4
B A Gusterson, R D Gelber, A Goldhirsch, K N Price, J Säve-Söderborgh, R Anbazhagan, J Styles, C M Rudenstam, R Golouh, R Reed, Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology. ,vol. 10, pp. 1049- 1056 ,(1992) , 10.1200/JCO.1992.10.7.1049
M F Press, L Bernstein, P A Thomas, L F Meisner, J Y Zhou, Y Ma, G Hung, R A Robinson, C Harris, A El-Naggar, D J Slamon, R N Phillips, J S Ross, S R Wolman, K J Flom, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology. ,vol. 15, pp. 2894- 2904 ,(1997) , 10.1200/JCO.1997.15.8.2894
C Carlomagno, F Perrone, C Gallo, M De Laurentiis, R Lauria, A Morabito, G Pettinato, L Panico, A D'Antonio, A R Bianco, S De Placido, c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology. ,vol. 14, pp. 2702- 2708 ,(1996) , 10.1200/JCO.1996.14.10.2702
Alan L. Schechter, David F. Stern, Lalitha Vaidyanathan, Stuart J. Decker, Jeffrey A. Drebin, Mark I. Greene, Robert A. Weinberg, The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. ,vol. 312, pp. 513- 516 ,(1984) , 10.1038/312513A0
Rabiya S. Tuma, Trastuzumab Trials Steal Show at ASCO Meeting JNCI: Journal of the National Cancer Institute. ,vol. 97, pp. 870- 871 ,(2005) , 10.1093/JNCI/97.12.870
Hadi Yaziji, HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods JAMA. ,vol. 291, pp. 1972- 1977 ,(2004) , 10.1001/JAMA.291.16.1972
Marilyn A. Owens, Bruce C. Horten, Moacyr M. Da Silva, HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clinical Breast Cancer. ,vol. 5, pp. 63- 69 ,(2004) , 10.3816/CBC.2004.N.011
Gloria Peiró, Francisco I. Aranda, Encarnal Adrover, María Niveiro, Cristina Alenda, Artemio Payá, Javier Seguí, Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node–negative breast carcinoma: prognostic relevance☆ Human Pathology. ,vol. 38, pp. 26- 34 ,(2007) , 10.1016/J.HUMPATH.2006.07.013